When should hematuria be evaluated?

When to Work Up Hematuria

All patients with gross hematuria or microhematuria ≥3 RBC/HPF confirmed on urinalysis should undergo risk stratification using the 2025 AUA/SUFU system, with evaluation intensity determined by their risk category. 1

Initial Confirmation and Assessment

Before initiating any workup, confirm hematuria with proper urinalysis technique. For microhematuria (MH), the threshold is ≥3 RBC/HPF on microscopy 1.

Key initial steps:

• Perform history focusing on age, sex, smoking history (detailed pack-years), prior gross hematuria, irritative urinary symptoms, family history of urologic malignancies, and occupational/environmental exposures 1
• Physical examination including blood pressure measurement
• Serum creatinine to assess for medical renal disease 1
• Rule out transient causes: menstruation, vigorous exercise, sexual activity, recent urologic procedures, or urinary tract infection

Critical Pitfall: UTI-Related Hematuria

If UTI is present, treat first and recheck urinalysis at 12 weeks (not earlier) to allow natural resolution—retesting before 12 weeks leads to false-positive persistent hematuria in up to 79% of cases 2. Earlier rechecking at 4 weeks only achieves 38% resolution 2.

Risk Stratification System (2025 AUA/SUFU)

The updated 2025 guidelines provide three risk tiers based on malignancy risk 1:

Low/Negligible Risk (0%-0.4% malignancy risk):

• Women age <50 years OR Men age <40 years
• Never smoker or <10 pack-years
• 3-10 RBC/HPF on single urinalysis
• No additional urothelial cancer risk factors

Intermediate Risk (0.2%-3.1% malignancy risk):

• Women age 50-59 years OR Men age 40-59 years
• 10-30 pack-years smoking history
• 11-25 RBC/HPF on single urinalysis
• Low-risk patients with persistent 3-10 RBC/HPF on repeat urinalysis
• May have additional urothelial cancer risk factors

High Risk (1.3%-6.3% malignancy risk):

• Women or Men age ≥60 years

• 30 pack-years smoking history

• 25 RBC/HPF on single urinalysis

• Any history of gross hematuria (automatic high-risk regardless of other factors)
• Additional urothelial cancer risk factors present

When to Initiate Workup

Immediate Evaluation Required:

1. All gross hematuria (visible blood in urine)—this automatically places patients in high-risk category requiring full evaluation 1, 3
2. High-grade hematuria (>50 RBC/HPF) on single urinalysis 4
3. Asymptomatic microhematuria with ≥3 RBC/HPF on two of three properly collected urinalyses in intermediate or high-risk patients 4

Delayed/Conditional Evaluation:

• Low-risk patients: May undergo repeat urinalysis rather than immediate full workup. If repeat UA is negative, can discharge from hematuria evaluation given very low malignancy risk 3
• Post-UTI treatment: Wait 12 weeks before repeat testing 2

Triggers for Re-evaluation After Negative Workup:

Even after negative initial evaluation, re-initiate workup if 3:

• Development of gross hematuria
• Significant increase in degree of microhematuria
• New urologic symptoms emerge

Why This Matters: The Stakes

The urgency stems from bladder cancer being the most common malignancy in hematuria patients, optimally detected by cystoscopy (not imaging alone) 1. Delays in bladder cancer diagnosis increase cancer-specific mortality by 34% and all-cause mortality by 15% 1. However, given MH prevalence of 2.4%-31.1% in healthy populations with low malignancy rates, the 2025 guidelines aim to prevent over-evaluation of low-risk patients while ensuring high-risk patients receive timely cystoscopy 1.

Common Pitfalls to Avoid

1. Under-evaluation: Using imaging alone without cystoscopy misses most bladder cancers 1
2. Premature retesting after UTI: Leads to unnecessary evaluations when hematuria would have resolved naturally 2
3. Ignoring gross hematuria history: Even a single episode of gross hematuria places patients in high-risk category requiring full evaluation 1
4. Inadequate smoking history: Must document detailed pack-years, as this is the strongest modifiable risk factor 1
5. Missing repeat confirmation: For asymptomatic MH, require 2 of 3 positive urinalyses before full workup in appropriate risk groups 4

The 2025 updated risk stratification system represents the most current evidence-based approach, refining the 2020 guidelines with validation data showing clear malignancy risk differences across the three tiers 1.